CFZ533: Assessment of Immunomodulatory Activity Following Single Doses of a Novel Anti-CD40 mAb in Healthy Volunteers

被引：0
|
作者：
Slade, A. [1 ]
Doucet, J. [2 ]
Koo, P. [1 ]
Espie, P. [2 ]
Rush, J. [2 ]
Tomek, C. [3 ]
Klupp, J. [2 ]
机构：
[1] Novartis Inst Biomed Res, E Hanover, NJ USA
[2] Novartis Inst Biomed Res, Basel, Switzerland
[3] Celerion Inc, Lincoln, NE USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2015年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
2007
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ASSESSMENT OF SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF A NOVEL ANTI-CD40 MONOCLONAL ANTIBODY, CFZ533, IN HEALTHY VOLUNTEERS
    Slade, Alan
    Koo, Philip
    Espie, Pascal
    Auger-Sarrazin, Anita
    Rush, James S.
    Tomek, Charles
    Haraldsson, Boerje
    Klupp, Jochen
    TRANSPLANT INTERNATIONAL, 2015, 28 : 600 - 600
  • [2] CFZ533: SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF A NOVEL ANTI-CD40 ANTIBODY IN HEALTHY VOLUNTEERS
    Slade, Alan
    Koo, Philip
    Espie, Pascal
    Rush, James
    Tomek, Charles
    Haraldsson, Boerje
    Klupp, Jochen
    TRANSPLANT INTERNATIONAL, 2015, 28 : 492 - 492
  • [3] Assessment of Safety, Pharmacokinetics and Pharmacodynamics of a Novel Anti-CD40 Monoclonal Antibody, CFZ533, in Healthy Volunteers and in Rheumatoid Arthritis Patients
    Slade, Alan
    Koo, Phillip
    He, Yanling
    Espie, Pascal
    Auger-Sarrazin, Anita
    Rush, James S.
    Gergely, Peter
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] ASSESSMENT OF SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF A NOVEL ANTI-CD40 MONOCLONAL ANTIBODY, CFZ533, IN HEALTHY VOLUNTEERS AND IN RHEUMATOID ARTHRITIS PATIENTS
    Slade, A.
    Koo, P.
    He, Y.
    Espie, P.
    Auger-Sarrazin, A.
    Rush, J.
    Gergely, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 516 - 517
  • [5] THE ANTI-CD40 MAB ISCALIMAB (CFZ533) DOES NOT IMPAIR IMMUNE EBV CONTROL
    Rubic-Schneider, Tina
    Garcia, Deborah
    Marchant, Martine
    Christen, Brigitte
    Runser-Loll, Nathalie
    Rush, James
    Traggiai, Elisabetta
    Ulrich, Peter
    TRANSPLANT INTERNATIONAL, 2019, 32 : 138 - 138
  • [6] Nonclinical Safety Assessment of CFZ533, a Fc-Silent Anti-CD40 Antibody, in Cynomolgus Monkeys
    Ulrich, Peter
    Flandre, Thierry
    Espie, Pascal
    Sickert, Denise
    Rubic-Schneider, Tina
    Shaw, David A.
    Rush, James S.
    TOXICOLOGICAL SCIENCES, 2018, 166 (01) : 192 - 202
  • [7] Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody
    Ristov, Jacinda
    Espie, Pascal
    Ulrich, Peter
    Sickert, Denise
    Flandre, Thierry
    Dimitrova, Mirela
    Mueller-Ristig, Dorothee
    Weider, Doris
    Robert, Gautier
    Schmutz, Patrick
    Greutmann, Barbara
    Cordoba-Castro, Francisco
    Schneider, Martin A.
    Warncke, Max
    Kolbinger, Frank
    Cote, Serge
    Heusser, Christoph
    Bruns, Christian
    Rush, James S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 (12) : 2895 - 2904
  • [8] The novel anti-CD40 monoclonal antibody CFZ533 modulates biomarkers relevant to disease and CD40 pathways in patients with primary Sjogren's syndrome
    Fisher, Benjamin
    Zeher, Margit
    Ng, Wan-Fai
    Bombardieri, Michele
    Posch, Maximilian
    Papas, Athena S.
    Farag, Arwa M.
    Daikeler, Thomas
    Bannert, Bettina
    Kivitz, Alan J.
    Carsons, Steven E.
    Isenberg, David A.
    Barone, Francesca
    Bowman, Simon
    Espie, Pascal
    Wieczorek, Grazyna
    Moulin, Pierre
    Floch, David
    Dupuy, Cyrielle
    Ren, Xiaohui
    Faerber, Petra
    Wright, Andrew M.
    Hockey, Hans Ulrich
    Rotte, Michael
    Healey, Margaret
    Kazma, Remi
    Sarrazin, Anita Auger
    Kaiser, Stephanie
    Mueller, Eric Chen Annemarie
    Wache-Mainier, Clarisse
    Macchiarella, Giulio
    Avrameas, Alexandre
    Sommer, Ulrike
    Valentin, Marie-Anne
    Doucet, Julie
    Sultan, Marc
    Schlitt, Thomas
    Gergely, Peter
    Rush, James S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (03) : S245 - S246
  • [9] CFZ533, a New Anti-CD40 mAB Demonstrates Comparable Efficacy and Better Renal Function versus Tacrolimus in De-Novo CNI-Free Kidney Transplantation.
    Nashan, B.
    Tedesco, H.
    van den Hoogen, M.
    Berger, S.
    Cibrik, D.
    Mulgaonkar, S.
    Leeser, D.
    Alloway, R.
    Patel, A.
    Pratschke, J.
    Sommerer, C.
    Wiseman, A.
    van Zuilen, A.
    Laessing, U.
    Rush, J.
    Haraldsson, B.
    Witzke, O.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 400 - 400
  • [10] Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study
    Flandre, Thierry D.
    Mansfield, Keith G.
    Espie, Pascal J.
    Rubic-Schneider, Tina
    Ulrich, Peter
    TOXICOLOGIC PATHOLOGY, 2022, 50 (05) : 712 - 724
12345